Examination of suppressive effect by combined treatment of orthokeratology and atropine 0.01% ophthalmic solution on myopia progression

Examination of suppressive effect by combined treatment of orthokeratology and atropine 0.01% ophthalmic solution on myopia progression - Preventing myopia progression which combined orthokeratology and atropine 0.01% ophthalmic solution

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014362

Enrollment

Registered

2014-06-24

Start date

2014-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Orthokeratology contact lens Atropine 0.01% ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Cycloplegic spherical equivalent refractive error of -1.00 to -6.00 D in both eyes 2) Astigmatism of less than 1.50 D in both eyes 3) Anisometropia of less than 1.50 D 4) Best corrected visual acuity of more than 1.0 in both eyes

Exclusion criteria

Exclusion criteria: 1) Eye disorders such as strabismus and amblyopia 2) Systemic disorders such as cardiac or respiratory illness 3) Birth weight of less than 1500 g 4) History of hypersensitivity to atropine 5) Using of orthokeratology and/or atropine ophthalmic solutions

Design outcomes

Primary

Measure	Time frame
Efficacy: Increase in axial length over a 2-year period	—

Secondary

Measure	Time frame
Safty: Decrease in corneal endothelial cell density over a 2-year period Efficacy: Increase in axial length over a 1-year period Safty: Decrease in corneal endothelial cell density over a 1-year period	—

Countries

Japan

Contacts

Public ContactNozomi Kinoshita

Saitama Medical Center, Jichi Medical University Department of Ophthalmology

nozomik@omiya.jichi.ac.jp048-647-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026